Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study.

Subjects

Subjects :

Nitriles
Pyrazoles pharmacology
Pyrazoles therapeutic use
Pyrimidines
Retrospective Studies
Janus Kinase Inhibitors pharmacology
Myelodysplastic Syndromes drug therapy
Skin Diseases, Genetic drug therapy

Details

Language :

English

ISSN :

1528-0020

Volume :

140

Issue :

8

Database :

MEDLINE

Journal :

Blood

Publication Type :

Academic Journal

Accession number :

35609174

Full Text :

https://doi.org/10.1182/blood.2022016642